Pharmaceutical composition for improving postpartum health level of dairy cows and application of pharmaceutical composition

Abstract

The invention belongs to the technical field of traditional Chinese veterinary medicines, and particularly relates to a pharmaceutical composition for improving the postpartum health level of dairy cows and application of the pharmaceutical composition. The pharmaceutical composition comprises radix paeoniae alba, cassia twigs, peach kernels, ligusticum wallichii, immature bitter oranges, poria cocos and honey-fried licorice roots according to a specific ratio, can effectively promote the recovery of the feed intake and milk yield of the dairy cows in the perinatal period, can also reduce the risk that the dairy cows in the perinatal period suffer from diseases such as hysteritis, and is beneficial to the recovery of the postpartum production performance of the dairy cows.

Description

A pharmaceutical composition for improving the postpartum health of dairy cows and its application Technical Field

[0001] This invention belongs to the field of traditional Chinese veterinary medicine preparations, and specifically relates to a pharmaceutical composition for improving the postpartum health of dairy cows and its application. Background Technology

[0002] The peripartum period is the most critical stage in the dairy cow's production cycle. Dairy cows experience various stresses such as calving, herding, feed changes, and energy metabolism disorders. Most dairy cows will experience one or more diseases after calving. Postpartum diseases can easily lead to decreased feed intake and milk production in dairy cows after calving. They can also increase the incidence of peripartum diseases such as delayed uterine involution, retained placenta, ketosis, and metritis. At the same time, dairy cow deaths mainly occur within 21 days after calving, which seriously threatens the healthy development of the dairy industry.

[0003] Currently, the main clinical methods for preventing peripartum diseases in dairy cows are injecting chemical drugs such as oxytocin, diclofenac, meloxicam, and antibiotics after calving. However, these drugs may cause chemical residues in milk and may also cause gastrointestinal discomfort, leading to decreased gastrointestinal digestive function or even gastric ulcers in dairy cows.

[0004] In the field of traditional Chinese veterinary medicine, there are currently drugs available on the market for treating postpartum discomfort in dairy cows. These include "Guiqi Yimu Oral Liquid," which has the effects of replenishing qi and blood, promoting blood circulation and removing blood stasis, and is mainly used to treat postpartum qi deficiency and blood stasis syndrome in dairy cows, characterized by fatigue, loss of appetite, swollen vulva, prolonged lochia, abdominal pain, or retained placenta; "Yimu Shenghua Powder," which has the effects of promoting blood circulation, removing blood stasis, warming the meridians, and relieving pain, and is mainly used to treat postpartum lochia retention and blood stasis abdominal pain; and "Buyi Qinggong Powder," which has the effects of replenishing qi and blood, promoting blood circulation and removing blood stasis, and is mainly used to treat postpartum qi and blood deficiency, retained placenta, prolonged lochia, and blood stasis abdominal pain. Although these drugs are used to prevent and treat postpartum diseases in dairy cows, their formulations and indications are mainly focused on blood stasis and abdominal pain, resulting in a narrow range of applications and a weak effect on improving the overall health of dairy cows during the peripartum period.

[0005] Therefore, developing a safe, effective, and low-side-effect veterinary Chinese medicine preparation that is highly targeted at dairy cows during the peripartum period and can significantly improve their overall health during this time is of great practical significance. Summary of the Invention

[0006] To address the shortcomings of existing technologies, this invention aims to provide a pharmaceutical composition for preventing and treating postpartum diseases in dairy cows and its application. The pharmaceutical composition includes a specific ratio of white peony root, cinnamon twig, peach kernel, chuanxiong rhizome, immature bitter orange, poria cocos, and prepared licorice root. This composition can effectively promote the recovery of feed intake and milk production in peripartum dairy cows, and can also reduce the risk of peripartum diseases such as metritis in dairy cows, which is beneficial to the recovery of postpartum health and production performance in dairy cows.

[0007] To achieve the above object, on the one hand, the present invention provides a pharmaceutical composition for improving the postpartum health level of dairy cows, and the composition comprises Paeonia lactiflora Pall., Cinnamomum cassia Presl, Prunus persica (L.) Batsch, Ligusticum wallichii Franch., Fructus aurantii Immaturus, Poria cocos (Schw.) Wolf, and Radix Glycyrrhizae Praeparata Cum Melle. The mass ratio of Paeonia lactiflora Pall., Cinnamomum cassia Presl, Prunus persica (L.) Batsch, Ligusticum wallichii Franch., Fructus aurantii Immaturus, Poria cocos (Schw.) Wolf, and Radix Glycyrrhizae Praeparata Cum Melle is 10 - 40:10 - 13:10 - 13:14 - 20:9 - 13:9 - 13:10 - 13.

[0008] Further, the composition consists of Paeonia lactiflora Pall., Cinnamomum cassia Presl, Prunus persica (L.) Batsch, Ligusticum wallichii Franch., Fructus aurantii Immaturus, Poria cocos (Schw.) Wolf, and Radix Glycyrrhizae Praeparata Cum Melle.

[0009] Further, the mass ratio of Paeonia lactiflora Pall., Cinnamomum cassia Presl, Prunus persica (L.) Batsch, Ligusticum wallichii Franch., Fructus aurantii Immaturus, Poria cocos (Schw.) Wolf, and Radix Glycyrrhizae Praeparata Cum Melle is 40:13:13:20:13:13:13.

[0010] The ratio of the pharmaceutical composition in the present invention has been verified by clinical trials and is most significant in preventing and treating perinatal diseases of dairy cows and comprehensive conditioning effects. From the perspective of traditional Chinese medicine theory, this formula follows the compatibility principle of "sovereign, ministerial, adjuvant, and courier".

[0011] Sovereign drug: Paeonia lactiflora Pall. is bitter, sour, and slightly cold. It belongs to the liver and spleen meridians. It has the effects of nourishing blood and regulating menstruation, astringing yin and stopping sweating, and soothing the liver and relieving pain. In this formula, Paeonia lactiflora Pall. has the largest dosage. On the one hand, it can significantly supplement the state of blood deficiency and fluid deficiency in dairy cows after parturition. At the same time, it can relieve spasm and pain, and can effectively relieve postpartum abdominal pain caused by childbirth. It is the sovereign drug.

[0012] Ministerial drug: Cinnamomum cassia Presl is pungent, sweet, and warm in nature. It belongs to the heart, lung, and bladder meridians. It has the effects of inducing sweating to relieve the exterior syndrome, warming the meridians to promote blood circulation, assisting yang to transform qi, and calming the adverse qi. In the formula, Cinnamomum cassia Presl, on the one hand, warms the meridians to dispel cold and promotes blood circulation through the meridians. On the other hand, it assists yang to transform qi, strengthens the healthy qi to eliminate pathogenic factors, and enhances the postpartum immunity of dairy cows. It is the ministerial drug.

[0013] Adjuvant drugs: Prunus persica (L.) Batsch is bitter, sweet, and neutral in nature. It belongs to the heart, liver, and large intestine meridians. It has the effects of promoting blood circulation to remove blood stasis, moistening the intestines and relieving constipation, and relieving cough and asthma. Ligusticum wallichii Franch. is pungent and warm in nature. It belongs to the liver, gallbladder, and pericardium meridians. It has the effects of promoting blood circulation and qi movement, dispelling wind and relieving pain. Fructus aurantii Immaturus is bitter, pungent, and sour, and slightly cold in nature. It belongs to the spleen and stomach meridians. It has the effects of breaking qi to eliminate accumulation and resolving phlegm and dissipating stagnation. In the formula, the combination of Prunus persica (L.) Batsch and Ligusticum wallichii Franch. enhances the function of promoting blood circulation to remove blood stasis, and the combination of Fructus aurantii Immaturus and Ligusticum wallichii Franch. enhances the function of promoting blood circulation and qi movement, jointly relieving the state of blood stasis and qi stagnation in dairy cows after parturition. They are adjuvant drugs.

[0014] Courier drug: Poria cocos (Schw.) Wolf is sweet, light, and neutral in nature. It belongs to the heart, lung, spleen, and kidney meridians. It has the effects of promoting diuresis to remove dampness, strengthening the spleen, and calming the mind. Radix Glycyrrhizae Praeparata Cum Melle is sweet and neutral in nature. It belongs to the heart, lung, spleen, and stomach meridians. It has the effects of invigorating the spleen and replenishing qi, relieving spasm and pain, and coordinating the actions of various drugs. In the formula, Poria cocos (Schw.) Wolf and Radix Glycyrrhizae Praeparata Cum Melle jointly replenish qi and strengthen the spleen, promote appetite, and enhance the gastrointestinal digestion function of dairy cows. At the same time, Radix Glycyrrhizae Praeparata Cum Melle is sweet and can replenish qi and blood, relieve spasm and pain, and enhance the pain-relieving effect of the sovereign drug. Therefore, Poria cocos (Schw.) Wolf and Radix Glycyrrhizae Praeparata Cum Melle are jointly the courier drugs.

[0015] Furthermore, the preparation method of the pharmaceutical composition includes the steps of raw material pulverization, sieving (e.g., sieving through an 80-100 mesh sieve), mixing, and dispensing.

[0016] In a second aspect, the present invention provides the use of the pharmaceutical composition described in the first aspect in the preparation of products capable of improving the postpartum health of dairy cows.

[0017] Furthermore, the dosage of the pharmaceutical composition is 700-800g / cattle.

[0018] Furthermore, the product is either animal feed or medicine.

[0019] Furthermore, the improvement of the postpartum health level of dairy cows includes at least one of the following: (1) increasing the feed intake, rumination time and / or feeding duration of dairy cows after calving; (2) increasing the amount of exercise of dairy cows after calving; (3) improving the milk yield and / or milk quality of dairy cows after calving; and (4) preventing and treating postpartum diseases of dairy cows.

[0020] Furthermore, the milk quality includes milk protein content and / or milk fat content.

[0021] Furthermore, the prevention and treatment of postpartum diseases in dairy cows includes reducing the incidence of metritis or peripartum diseases or promoting the speed of uterine involution in postpartum dairy cows, specifically including peripartum diseases such as metritis, retained placenta, mastitis, abomasal displacement, and digestive diseases.

[0022] Compared with the prior art, the present invention has the following advantages: (1) The present invention combines seven Chinese veterinary drugs, namely white peony root, cinnamon twig, peach kernel, chuanxiong rhizome, immature bitter orange, poria cocos and prepared licorice root, in a specific ratio to form a drug composition. Through the synergistic effect between the raw materials, it significantly promotes the improvement of the health level of dairy cows during the peripartum period.

[0023] (2) The pharmaceutical composition of the present invention can effectively promote the recovery of feed intake and milk production in periparturient dairy cows, reduce the risk of periparturient dairy cows suffering from diseases such as metritis, and is conducive to the comprehensive and effective recovery of dairy cows' postpartum health and production performance.

[0024] (3) The preparation process of the pharmaceutical composition of the present invention is simple, suitable for industrial production, and can retain the activity of the medicinal materials to the greatest extent. Attached Figure Description

[0025] Figure 1. Milk production of dairy cows in different groups 30 days postpartum in Example 1.

[0026] Figure 2. Milk production of different groups of dairy cows 30 days postpartum in Example 2.

[0027] Figure 3. Rumination time before and after calving in different groups of dairy cows in Example 2.

[0028] Figure 4. Pre- and post-partum exercise levels of dairy cows in different groups in Example 2.

[0029] Figure 5. Milk production of dairy cows in the same group 30 days postpartum in Example 3.

[0030] Figure 6. DHI milk quality of different groups of dairy cows in Example 3 during the first month after calving.

[0031] Figure 7. Blood ketone levels of different groups of dairy cows on the 14th day postpartum in Example 3.

[0032] Figure 8. Postpartum uterine involution score results of different groups of dairy cows in Example 3.

[0033] Figure 9. Feeding time of dairy cows in different groups before and after calving in Example 3.

[0034] Figure 10. Milk production of different groups of dairy cows 30 days postpartum in Example 4.

[0035] Figure 11. Blood ketone levels of different groups of dairy cows on the 14th day after calving in Example 4. Figure 12. Schematic diagram of the postpartum administration of medication to dairy cows.

[0036] Figure 13. Schematic diagram of postpartum care examination and blood collection in dairy cows. Detailed Implementation

[0037] The following detailed embodiments further illustrate the concept and technical effects of the present invention to fully understand its purpose, features, and effects. Unless otherwise specified, all methods described are conventional methods. Unless otherwise specified, all materials are available from publicly available commercial sources. The illustrative embodiments and descriptions of the present invention are used to explain the invention and do not constitute an undue limitation thereof. It should be noted that, unless otherwise specified, the embodiments and features described in the present invention can be combined with each other.

[0038] Example 1: Preliminary prescription screening test. The test was conducted at a large-scale ranch in Shaanxi Province, using three compound prescriptions to screen prescription components.

[0039] (I) Experimental drug prescription 1: Astragalus membranaceus 25 parts, Angelica sinensis 8 parts, Ligusticum chuanxiong 8 parts, Leonurus japonicus 16 parts, Cinnamomum cassia 13 parts, Ziziphus jujuba 16 parts, Zingiber officinale 13 parts.

[0040] Prescription 2: Astragalus membranaceus 23 parts, Ligusticum chuanxiong 15 parts, Leonurus japonicus 15 parts, Cinnamomum cassia 12 parts, Sophora flavescens 8 parts, Cnidium monnieri 8 parts, Rheum palmatum 5 parts, Paederia scandens 15 parts.

[0041] Prescription 3: Chuanxiong 14 parts, Guizhi 9 parts, Shudi 14 parts, Zhigancao 9 parts, Ganjiang 9 parts, Dazao 7 parts, Kushen 6 parts, Shechuangzi 6 parts, Yimucao 9 parts, Xiangfu 7 parts, Jishiteng 9 parts.

[0042] Control group: No treatment received. (II) Experimental Methods: 38 newly calved dairy cows were selected and divided into 4 groups: control group (n=10), prescription group 1 (n=9), prescription group 2 (n=9), and prescription group 3 (n=10). Cows in prescription groups 1, 2, and 3 received 755g of each prescription daily for 3 consecutive days postpartum. The control group received no medication. Finally, the incidence of peripartum diseases in each group was statistically analyzed to observe the effects of traditional Chinese veterinary medicine on the incidence of peripartum diseases and milk production performance in dairy cows.

[0043] (III) Experimental Results The disease incidence rates in dairy cows during the peripartum period (21 days postpartum) are shown in Table 1. Regarding the incidence of metritis, Prescription Group 3 showed the largest decrease, with a reduction of 30 percentage points compared to the control group (10.00% vs 40.00%). In terms of overall disease incidence, the control group had a peripartum disease incidence rate of 40.00%, Prescription Group 1 had 44.44%, Prescription Group 2 had 44.44%, and Prescription Group 3 had 20.00%. Prescription Group 3 showed the largest decrease, with a reduction of 20 percentage points compared to the control group (20.00% vs 40.00%). These results indicate that Prescription 3 can reduce the incidence of postpartum metritis and the overall disease incidence rate in dairy cows, thus improving their postpartum health.

[0044] Figure 1 shows the results of milk production performance 30 days postpartum. Milk yield increased in all groups. The control group showed a slower increase in milk yield. Both prescriptions 1 and 3 effectively increased and maintained high milk yields, with prescription 3 showing a faster initial increase but greater fluctuations. The effect of prescription 2 declined in the later stages. These results indicate that prescription 3 has a certain effect on improving milk production performance in dairy cows.

[0045] Table 1. Statistical table of peripartum disease incidence in dairy cows of different groups

[0046] Example 2 Prescription Screening and Treatment Course Screening Trial (I) As can be seen from the results of Example 1, prescription three has the best effect among the three prescriptions. Therefore, a further formulation optimization test of prescription three was conducted at a large-scale ranch in Ningxia. At the same time, the scale of the test was expanded and the number of administrations was reduced to observe the effect of administering the medication only once during calving on the prevention and treatment of peripartum diseases in dairy cows.

[0047] (I) Experimental drug prescription 1: 28 parts of white peony root, 9 parts of cinnamon twig, 13 parts of motherwort, 14 parts of chuanxiong rhizome, and 14 parts of prepared licorice root. Prescription 2: 28 parts of white peony root, 9 parts of cinnamon twig, 9 parts of motherwort, 14 parts of chuanxiong rhizome, 7 parts of cyperus rhizome, 8 parts of chicken dung vine, and 9 parts of prepared licorice root.

[0048] Prescription 3: 40 parts white peony root, 13 parts cinnamon twig, 13 parts peach kernel, 20 parts chuanxiong rhizome, 13 parts immature bitter orange, 13 parts poria cocos, and 13 parts prepared licorice root.

[0049] Control group: No treatment received. (II) Experimental Methods: 318 newly calved dairy cows were selected and divided into four groups: control group (n=80), Prescription 1 (n=80), Prescription 2 (n=80), and Prescription 3 (n=78). Cows in Prescription 1, Prescription 2, and Prescription 3 were administered 755g of each prescription orally once at the postpartum pasture. The control group received no treatment. Finally, the incidence of peripartum diseases in each group was statistically analyzed to observe the effects of traditional Chinese veterinary medicine on the incidence of peripartum diseases, milk production performance, rumination time, and activity level in dairy cows.

[0050] (III) Experimental Results The disease incidence rates in dairy cows during the peripartum period (21 days postpartum) are shown in Table 2. Regarding the incidence of metritis, the incidence rate in prescription group 3 was 14.55 percentage points lower than that in the control group (17.95% vs 32.50%), showing the largest decrease, which was statistically significant (P < 0.05). Regarding the overall disease incidence rate, the overall disease incidence rate in the control group was 46.25%, prescription group 1 was 37.50%, prescription group 2 was 25.00%, and prescription group 3 was 20.51%. Prescription group 3 showed the largest decrease compared to the control group, at 25.74 percentage points (20.51% vs 46.25%), which was statistically significant (P < 0.01). These results indicate that prescription 3 can significantly reduce the incidence of postpartum metritis and the overall disease incidence rate in dairy cows, and significantly improve their postpartum health.

[0051] Figure 2 shows the results of milk production performance in dairy cows 30 days postpartum. On the first day postpartum, the milk yield of prescription 3 was higher than that of prescription 1, prescription 2, and the control group. There was a statistically significant difference between prescription 3 and the control group (P < 0.05). Subsequently, the milk yield of each group steadily increased, with prescription 3 showing the highest milk production, which remained at a high level and exhibited a stable growth trend. These results indicate that prescription 3 has a certain effect on improving the milk production performance of dairy cows.

[0052] Figure 3 shows the results of rumination time in dairy cows from 7 days before calving to 21 days postpartum. There was no significant difference in feeding time among the groups before calving (P > 0.05). However, after calving, the rumination time of cows treated with prescription three remained at the highest level, and the rumination time from 2 to 21 days postpartum was significantly higher than that of the control group, with statistically significant differences (P < 0.05). These results indicate that prescription three can effectively improve postpartum rumination time in dairy cows and effectively enhance the recovery of postpartum gastrointestinal function.

[0053] Figure 4 shows the results of cow activity levels from 7 days before calving to 21 days postpartum. Before calving, the activity levels of cows in each group remained stable with no significant differences. However, one week postpartum, the activity levels of cows in all groups began to decline sharply, subsequently fluctuating within a relatively stable range. Prescription 3 showed the lowest decline in activity levels, remaining at the highest level, and exhibited statistically significant differences compared to the control group on days 2, 3, 8, and 10 postpartum (d2, d3, d8, d10) (P < 0.05). These results indicate that Prescription 3 can significantly alleviate the sharp decline in postpartum activity levels in cows, reduce postpartum discomfort, and thus promote cow health.

[0054] Table 2. Statistical table of peripartum disease incidence in dairy cows of different groups

[0055] Note: * indicates a significant difference between each group and the control, *P<0.05, **P<0.01, ***P<0.001.

[0056] Example 3: Prescription Screening and Dosage Screening Experiment (II) As can be seen from Example 2, the treatment course is one dose postpartum. Among the three prescriptions, prescription three showed the best effect. However, to determine the optimal treatment course, this experiment involved three postpartum oral administrations to observe the effects of traditional Chinese medicine prescriptions on peripartum diseases in dairy cows. The experiment was conducted at a large-scale ranch in Heilongjiang Province.

[0057] (I) Experimental drug prescription 1: 28 parts of white peony root, 9 parts of cinnamon twig, 13 parts of motherwort, 14 parts of chuanxiong rhizome, and 14 parts of prepared licorice root.

[0058] Prescription 2: White peony root 28 parts, cinnamon twig 9 parts, motherwort 9 parts, chuanxiong rhizome 14 parts, cyperus rhizome 7 parts, chicken dung vine 8 parts, prepared licorice root 9 parts.

[0059] Prescription 3: 40 parts white peony root, 13 parts cinnamon twig, 13 parts peach kernel, 20 parts chuanxiong rhizome, 13 parts immature bitter orange, 13 parts poria cocos, and 13 parts prepared licorice root.

[0060] Positive drug group: Yimu Shenghua San; Control group: No treatment. (II) Experimental method: 88 newborn dairy cows were selected and divided into 5 groups: control group (n=18), positive drug group (n=18), prescription group 1 (n=17), prescription group 2 (n=18), and prescription group 3 (n=17). The cows in the positive drug group, prescription group 1, prescription group 2, and prescription group 3 were administered 755g of each prescription daily for 3 consecutive days after calving. The control group received no treatment. The incidence of peripartum diseases in each group was statistically analyzed to observe the effects of traditional Chinese veterinary medicine on the incidence of peripartum diseases, milk production performance, milk quality, uterine involution score, and feeding time in dairy cows.

[0061] (III) Experimental Results The disease incidence rates in dairy cows during the peripartum period (21 days postpartum) are shown in Table 3. Regarding the incidence of metritis, the incidence rate in prescription group 3 was 21.57 percentage points lower than the control group (11.76% vs 33.33%), showing the largest decrease. In terms of the overall incidence rate, the control group was 44.44%, the positive control group was 33.33%, prescription group 1 was 29.41%, prescription group 2 was 33.33%, and prescription group 3 was 17.65%. Prescription group 3 showed the largest decrease, 26.79 percentage points lower than the control group (17.65% vs 44.44%). These results indicate that prescription 3 can reduce the incidence of postpartum metritis and the overall incidence rate in dairy cows, improving their postpartum health.

[0062] Figure 5 shows the results of milk production performance in dairy cows 30 days postpartum. Milk production steadily increased in all groups postpartum, with Formula 3 showing the highest milk yield. Furthermore, Formula 3's milk production on days 6-9, 12, and 20-30 postpartum (d6-9, d12, d20-30) was significantly higher than the control group, with statistically significant differences (P < 0.05), and the growth trend was stable. These results indicate that Formula 3 can significantly improve postpartum milk production performance in dairy cows.

[0063] Figure 6 shows the results of DHI milk quality testing in the first month postpartum. Regarding milk fat content, Prescription 3 had the highest content, and there was a statistically significant difference compared to Prescriptions 1 and 2 (P < 0.05). Regarding milk protein content, Prescription 3 also had the highest content, and there were statistically significant differences compared to Prescriptions 1, 2, the positive control group, and the blank control group (P < 0.05). There were no significant differences in lactose content among the groups. At the somatic cell count level, Prescription 3 had the lowest level, but there was no statistically significant difference (P > 0.05). These results indicate that Prescription 3 can increase milk fat and milk protein content, reduce somatic cell count, and improve milk quality in dairy cows.

[0064] Figure 7 shows the results of blood ketone testing in dairy cows on day 14 postpartum. The overall blood ketone level of prescription three was the lowest, and the blood ketone levels of each group remained within the normal physiological range (BHBA < 1.2 mmol / L). This indicates that prescription three has a tendency to improve the negative energy balance in dairy cows after calving, improve the postpartum health of dairy cows, and will not affect the energy metabolism problem in dairy cows after calving.

[0065] Figure 8 shows the results of the uterine involution score of dairy cows 21 days postpartum. The scores of prescription group 3 were lower than those of other groups at 7, 14 and 21 days postpartum. In particular, there were statistically significant differences between prescription group 3 and the control group at 7 and 14 days postpartum (P < 0.05), indicating that prescription 3 has a significant effect on promoting uterine involution in dairy cows after calving.

[0066] Figure 9 shows the results of feeding time in dairy cows from 7 days before calving to 21 days after calving. The feeding time of dairy cows in each group was basically the same before and after calving, with no statistical difference (P>0.05). However, on the day of calving (d0), the feeding time of prescription group 3 was significantly increased, and there was a statistical difference compared with the control group (P<0.05), indicating that prescription 3 can promote the recovery of appetite in dairy cows on the day of calving.

[0067] Table 3. Statistical table of peripartum disease incidence in dairy cows of different groups

[0068] Example 4: Preparation of the Drug Composition and Feeding Trial in Dairy Cows. As can be seen from Examples 3 and 2, Formula 3 showed the best effect among the three formulations. Furthermore, compared to the control group, Formula 3, administered once postpartum and three times postpartum, resulted in a reduction of approximately 50% in the incidence of postpartum metritis (44.77% vs 64.72%), and a reduction of approximately 55%–60% in the total incidence of perinatal diseases (55.65% vs 60.28%), with no significant difference (P > 0.05). Therefore, based on the two trials, Formula 3 is currently the most effective formulation, and a cost-effective treatment course is a single postpartum administration. To further determine whether there is a synergistic effect among the individual drugs in Formula 3, the following experiments were conducted.

[0069] (I) Experimental Drug Blank Group Control Group: Administered an equal volume of water by gavage; Positive Drug Group: Administered Yimu Shenghua Powder by gavage; Experimental Case 1: A traditional Chinese veterinary medicine composition consisting of 40 parts white peony root, 13 parts cinnamon twig, 13 parts peach kernel, 20 parts chuanxiong rhizome, 13 parts immature bitter orange, 13 parts poria cocos, and 13 parts prepared licorice root; Experimental Case 2: A traditional Chinese veterinary medicine composition consisting of 10 parts white peony root, 10 parts cinnamon twig, 10 parts peach kernel, 15 parts chuanxiong rhizome, 10 parts immature bitter orange, 10 parts poria cocos, and 10 parts prepared licorice root; Experimental Case 3: A traditional Chinese veterinary medicine composition consisting of 15 parts white peony root, 12 parts cinnamon twig, 12 parts peach kernel, 14 parts chuanxiong rhizome, 9 parts immature bitter orange, 9 parts poria cocos, and 12 parts prepared licorice root; Control Group 1: A traditional Chinese veterinary medicine composition containing only white peony root; Control Group 2: A traditional Chinese veterinary medicine composition containing only cinnamon twig; Control Group 3: A traditional Chinese veterinary medicine composition containing only white peony root. A traditional Chinese veterinary medicine composition containing peach kernel was used in the experiment. Group 4 consisted of a traditional Chinese veterinary medicine composition containing only chuanxiong rhizome; Group 5 consisted of a traditional Chinese veterinary medicine composition containing only zhi shi (fragrant orange peel); Group 6 consisted of a traditional Chinese veterinary medicine composition containing only fu ling (Poria cocos); and Group 7 consisted of a traditional Chinese veterinary medicine composition containing only prepared licorice root. Experimental methods: 180 newly calved dairy cows were selected and divided into 12 groups (n=15): a blank control group, a positive drug group, experimental case 1, experimental case 2, experimental case 3, and control groups 1, 2, 3, 4, 5, 6, and 7. Each drug group received 755g of each prescription diluted in 8L of water at approximately 35-40℃ after calving, stirred well, and administered once. The blank control group received 8L of water at approximately 35-40℃ without the drug. The effects of traditional Chinese veterinary medicine on the incidence of peripartum diseases and milk production performance in dairy cows were observed.

[0070] (IV) Experimental Results The incidence rates of peripartum diseases (21 days postpartum) in dairy cows, including metritis, retained placenta, mastitis, abomasal displacement, and digestive disorders, are shown in Table 4. Regarding the incidence of metritis, the incidence rate in Experimental Case 1 was 13.33%, lower than that in the positive drug group and all control groups. In terms of the overall incidence rate, Experimental Cases 1-3 were all lower than those in Control Groups 1-7. These results indicate that the experimental groups can effectively reduce the overall incidence rate of postpartum diseases in dairy cows. The seven medicinal ingredients in the experimental groups have a synergistic effect in reducing postpartum disease incidence in dairy cows, effectively improving their postpartum health.

[0071] Figure 10 shows the results of milk production performance in dairy cows 30 days postpartum. During the 30-day postpartum period, milk yield in all groups showed an increasing trend, indicating that each group had a certain effect on improving milk production performance. Group 1 maintained the highest level and was significantly higher than the control group on day 22 (d22), with a statistically significant difference (P < 0.05). Milk yield in Group 1 was higher than in control groups 1-7 from day 6 to day 30 postpartum (d6-30), indicating that the seven herbs in Group 1 had a synergistic effect in increasing milk yield.

[0072] The results of blood ketone testing on day 14 postpartum are shown in Figure 11. The blood ketone levels in each group remained within the normal physiological range (BHBA < 1.2 mmol / L), indicating that the treatments did not affect the postpartum energy metabolism of dairy cows.

[0073] Table 4. Statistical table of peripartum disease incidence in dairy cows of different groups

[0074] The embodiments described above are only some embodiments of the present invention, not all embodiments. Other embodiments obtained by those skilled in the art based on the embodiments of the present invention without creative effort are all within the scope of protection of the present invention.

Claims

1. A pharmaceutical composition for improving the postpartum health of dairy cows, characterized in that, The composition comprises white peony root, cinnamon twig, peach kernel, chuanxiong rhizome, immature bitter orange, poria cocos, and prepared licorice root, wherein the mass ratio of white peony root, cinnamon twig, peach kernel, chuanxiong rhizome, immature bitter orange, poria cocos, and prepared licorice root is 10-40:10-13:10-13:14-20:9-13:9-13:10-13.

2. The pharmaceutical composition according to claim 1, characterized in that, The mass ratio of the following ingredients is 40:13:13:20:13:13:

13.

3. The pharmaceutical composition according to claim 1 or 2, characterized in that, The preparation method of the pharmaceutical composition includes the steps of raw material pulverization, sieving, mixing and packaging.

4. The use of the pharmaceutical composition according to claim 1 or 2 in the preparation of a product capable of improving the postpartum health of dairy cows, characterized in that, The product is either animal feed or medicine.

5. The application according to claim 4, characterized in that, The application is in the preparation of products that improve postpartum feed intake, rumination time, and / or feeding duration in dairy cows.

6. The application according to claim 4, characterized in that, The application is in the preparation of products that increase the amount of exercise in dairy cows after calving.

7. The application according to claim 4, characterized in that, The application is in the preparation of products that improve the milk yield and / or milk quality of dairy cows after calving.

8. The application according to claim 7, characterized in that, The quality of the milk produced includes the milk protein content and / or milk fat content.

9. The application according to claim 4, characterized in that, The application is in the preparation of products for the prevention and treatment of postpartum diseases in dairy cows.

10. The application according to claim 9, characterized in that, The postpartum conditions mentioned include endometritis, retained placenta, mastitis, abomasal displacement, or digestive disorders.

Images